Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Tuberc Lung Dis. 2012;16(3):358-63. doi: 10.5588/ijtld.11.0493.

Linezolid in the treatment of MDR-TB: a retrospective clinical study.

Author information

1
Department of Clinical Pharmacy, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. xuhongbin119@yahoo.cn

Abstract

BACKGROUND:

There is limited information on Chinese patients with multidrug-resistant tuberculosis (MDR-TB) treated with a linezolid-containing regimen.

OBJECTIVE:

To examine treatment outcomes among MDR-TB patients who were treated with linezolid at the Shanghai Pulmonary Hospital, China.

DESIGN:

We retrospectively reviewed 151 patients who were treated for MDR-TB from 2007 to 2010.

RESULTS:

Eighteen MDR-TB patients, including 15 with extensively drug-resistant TB, received linezolid as part of their individualised treatment regimens. Patients had isolates resistant to a median of 7 drugs (range 5-11). Of the 18 cases, 17 had cavitary changes and positive sputum smear microscopy results at the time of MDR-TB diagnosis. Culture conversion occurred in all cases at a median of 7 weeks. At data censure, 9 of the 18 patients had achieved treatment success. Three continued to receive treatment. There were no deaths. Six patients had a poor outcome, including 1 default, 2 treatment failures and 3 relapses. Side effects occurred in 17 patients, including myelosuppression, neurotoxicity and gastrointestinal adverse events. Adverse events were managed by combinations of temporary suspension of linezolid in 1 patient, dose adjustment in 17 patients and symptom management in 13 patients.

CONCLUSIONS:

Linezolid may have efficacy in the treatment of MDR-TB, although treatment was complicated by adverse events.

PMID:
22640450
DOI:
10.5588/ijtld.11.0493
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Ingenta plc
    Loading ...
    Support Center